Seeking Alpha

Teva (TEVA) files a petition with the FDA requesting the agency task an outside panel to...

Teva (TEVA) files a petition with the FDA requesting the agency task an outside panel to evaluate the safety of Biogen's (BIIB) multiple sclerosis drug, BG-12, before approval due to concerns over potential risks to the kidney. The drug is a potential competitor to TEVA's Copaxone, and if the request is granted, the drug's launch could be delayed.
Comments (2)
  • doc47
    , contributor
    Comments (1120) | Send Message
     
    A typical cheap shot. Do they think the FDA just approves drugs like this without exhaustive tests?
    9 Jan 2013, 06:52 PM Reply Like
  • CCONE62
    , contributor
    Comment (1) | Send Message
     
    For those of us with MS waiting for alternatives to daily injections, this is bad news. Come on Drug Makers, it's not about the bank roll, it's about what's best for those with the disease!!!!
    10 Jan 2013, 08:24 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector